Compare Glenmark Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUN PHARMA GLENMARK PHARMA/
SUN PHARMA
 
P/E (TTM) x 11.2 58.2 19.2% View Chart
P/BV x 1.6 4.3 37.0% View Chart
Dividend Yield % 0.6 0.9 69.9%  

Financials

 GLENMARK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
SUN PHARMA
Mar-21
GLENMARK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs573654 87.6%   
Low Rs195339 57.7%   
Sales per share (Unadj.) Rs387.8139.6 277.8%  
Earnings per share (Unadj.) Rs34.49.5 361.0%  
Cash flow per share (Unadj.) Rs50.118.2 275.4%  
Dividends per share (Unadj.) Rs2.507.50 33.3%  
Avg Dividend yield %0.71.5 43.1%  
Book value per share (Unadj.) Rs249.6193.6 128.9%  
Shares outstanding (eoy) m282.172,399.34 11.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.03.6 27.9%   
Avg P/E ratio x11.252.1 21.4%  
P/CF ratio (eoy) x7.727.3 28.1%  
Price / Book Value ratio x1.52.6 60.0%  
Dividend payout %7.378.8 9.2%   
Avg Mkt Cap Rs m108,3531,190,430 9.1%   
No. of employees `000NANA-   
Total wages/salary Rs m23,43768,622 34.2%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m109,439334,981 32.7%  
Other income Rs m5028,592 5.8%   
Total revenues Rs m109,941343,573 32.0%   
Gross profit Rs m21,28941,616 51.2%  
Depreciation Rs m4,43620,800 21.3%   
Interest Rs m3,5311,414 249.7%   
Profit before tax Rs m13,82527,994 49.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,1245,147 80.1%   
Profit after tax Rs m9,70122,847 42.5%  
Gross profit margin %19.512.4 156.6%  
Effective tax rate %29.818.4 162.2%   
Net profit margin %8.96.8 130.0%  
BALANCE SHEET DATA
Current assets Rs m73,596304,421 24.2%   
Current liabilities Rs m42,010161,456 26.0%   
Net working cap to sales %28.942.7 67.6%  
Current ratio x1.81.9 92.9%  
Inventory Days Days7149 4.4%  
Debtors Days Days8699 86.9%  
Net fixed assets Rs m67,093336,682 19.9%   
Share capital Rs m2822,399 11.8%   
"Free" reserves Rs m70,148462,229 15.2%   
Net worth Rs m70,430464,628 15.2%   
Long term debt Rs m38,8888,981 433.0%   
Total assets Rs m140,689641,103 21.9%  
Interest coverage x4.920.8 23.6%   
Debt to equity ratio x0.60 2,856.4%  
Sales to assets ratio x0.80.5 148.9%   
Return on assets %9.43.8 248.5%  
Return on equity %13.84.9 280.1%  
Return on capital %15.96.2 255.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m35,75384,493 42.3%   
Fx outflow Rs m12,02330,334 39.6%   
Net fx Rs m23,72954,159 43.8%   
CASH FLOW
From Operations Rs m11,31261,704 18.3%  
From Investments Rs m-6,7525,362 -125.9%  
From Financial Activity Rs m-4,418-59,805 7.4%  
Net Cashflow Rs m2785,964 4.7%  

Share Holding

Indian Promoters % 46.7 54.5 85.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 35.1 34.5 101.8%  
FIIs % 24.1 14.4 167.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 45.5 117.2%  
Shareholders   310,516 662,384 46.9%  
Pledged promoter(s) holding % 0.0 5.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    



Today's Market

Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)

After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)

Jul 30, 2021

Here's a rundown on Sun Pharma's June quarter results.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

Wait! Don't Buy the Smallcap 'Dip' Just Yet(Profit Hunter)

Jun 20, 2022

Why this may not be the best time to buy smallcaps.

5 Consistent Compounding Stocks Available at Discount. Time to Buy?(Views On News)

Jun 22, 2022

The good side of a market correction? Investors get consistent compounding stocks at a discount.

Looking for Value Stocks Amid Volatile Times? Consider These 5 Stocks(Views On News)

Jun 20, 2022

These value stocks have the potential to deliver good returns in the long run. Watch out for them.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 1, 2022 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS